VHL anticorps (AA 101-213) (Alexa Fluor 350)
-
- Antigène Voir toutes VHL Anticorps
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
-
Épitope
- AA 101-213
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp VHL est conjugé à/à la Alexa Fluor 350
-
Application
- Flow Cytometry (FACS), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- Réactivité croisée
- Humain
- Homologie
- Mouse,Rat,Dog,Cow
- Purification
- Purified by Protein A.
- Immunogène
- KLH conjugated synthetic peptide derived from human VHL
- Isotype
- IgG
- Top Product
- Discover our top product VHL Anticorps primaire
-
-
- Indications d'application
-
FCM 1:20-100
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Agent conservateur
- ProClin
- Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Date de péremption
- 12 months
-
- Antigène
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
- Autre désignation
- Vhl/Hrca1 (VHL Produits)
- Synonymes
- anticorps HRCA1, anticorps RCA1, anticorps VHL1, anticorps pVHL, anticorps BcDNA:RH61560, anticorps CG13221, anticorps DVhl, anticorps Dmel\\CG13221, anticorps Dvhl, anticorps VHL, anticorps d-VHL, anticorps d-vhl, anticorps dVHL, anticorps dmVHL, anticorps vhl, anticorps rca1, anticorps vhl1, anticorps hrca1, anticorps zgc:158722, anticorps Vhlh, anticorps von Hippel-Lindau tumor suppressor, anticorps von Hippel-Lindau, anticorps von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase, anticorps von Hippel-Lindau disease tumor suppressor, anticorps VHL, anticorps Vhl, anticorps vhl, anticorps CpipJ_CPIJ009992
- Sujet
-
Synonyms: Von Hippel Lindau, von Hippel-Lindau syndrome protein homolog, Hippel-Lindau disease tumor suppressor VHL, von Hippel-Lindau tumor suppressor isoform 1, VHL, HRCA1, RCA1, VHL1, von Hippel-Lindau disease tumor suppressor isoform 2,pVHL, pVHL, G7 protein, Elongin binding protein, Protein G7, VHL 1, VHL_HUMAN,VHL1, VHLH, Von Hippel Lindau disease tumor suppressor, von Hippel Lindau syndrome, von Hippel Lindau tumor suppressor, Von Hippel-Lindau disease tumor suppressor.
Background: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq].
- ID gène
- 7428
- Pathways
- Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
-